RTI Health Solutions (RTI-HS) is proud to announce that two of our researchers have been awarded fellowship status by the International Society for Pharmacoepidemiology (ISPE) Board of Directors. Both Alicia Gilsenan, PhD, RPh, and Andrea Margulis, MD, ScD, will be acknowledged as new FISPE...
On August 31, 2020, the FDA released its draft guidance titled “Principles for Selecting, Developing, Modifying, and Adapting Patient-Reported Outcome Instruments for Use in Medical Device Evaluation.”
The Author Awards Program, now in its 17th year, was established by the RTI Fellows as a way to recognize staff members
In advance of an approved COVID-19 vaccine, the European Medicines Agency (EMA) has commissioned research to monitor any vaccine that is approved for its safety and effectiveness in clinical practice.
Multiple myeloma (MM) is a type of blood cancer that occurs in our body’s plasma cells. Rapidly reproducing, cancerous cells collect in bone marrow and crowd out healthy cells. Myeloma cells produce antibodies that, instead of fighting off infection, cause problems such as kidney and bone damage...
Many biologic treatments are available for controlling symptoms of psoriasis. The treatments have varying purchase costs, dosing amounts and frequency, and real-world use. Therefore, understanding the total costs of these treatments to insurers can be difficult.
Experts on our Patient-Centered Outcomes Assessment (PCOA) team collaborated to create this best practices document to help research teams mitigate some of the impacts of COVID-19 on the collection and use of clinical outcome assessment (COA) data.
Combination expands offering of real-world data/real-world evidence (RWD/RWE) to the world’s leading pharmaceutical and biotech companies
by RTI-HS Health Economists Molly Purser, PhD and Naoko Ronquest, PhD
Healthy women over the age of 75 years might not benefit from continuing breast cancer screening.
RTI Health Solutions' parent company, RTI International, has been recognized by Forbes Magazine for its diverse workplace. The annual 2020 list of the ‘Best Employers for Diversity’—released each year by Forbes—ranked RTI #277 out of 500 companies based on a survey of nearly 60,000 employees at...
Recurring ear infections in children are not only frustrating and painful–they can also cause serious complications. If antibiotics do not successfully treat an ear infection or if infections continue to occur, a physician may recommend the insertion of ear tubes. Until now that has required the...
Answers to key questions about the communication of information for unapproved products as well as unapproved uses of approved products.
Pharmacoepidemiology, now in its sixth edition, provides comprehensive guidance available for anyone needing up-to-date information in pharmacoepidemiology.
We have conducted a review of publicly available information on scientific advice services offered by HTA bodies
Health technology assessments are becoming more influential in countries where payers were traditionally not using value-based pricing methods for pricing negotiations.
Respondents need to understand the survey questions if they are going to provide reliable data.
New office in Lyon, France, enhances our capabilities in real-world evidence generation
RTI Health Solutions' parent company, RTI International is a 2019 recipient of the Triangle Business Journal’s Leaders in Diversity award. The Leaders in Diversity Awards program, now in its seventh year, recognizes the accomplishments of Triangle businesses, individuals, and nonprofits who have...
To leverage ICER’s evaluations as opportunities to communicate the value of health technologies, we at RTI Health Solutions recommend a proactive, efficient, and strategic approach in preparing for each evaluation.
New research co-authored by RTI-HS researchers and published in Patient helps bring greater understanding of patient perspectives in hematologic cancers, particularly acute myeloid leukemia. The researchers analyzed information from a targeted literature review alongside patient-...
This study assesses the incidence rates of skeletal related events from the time of castration resistance.
Mary Beth was recommended for this honor by a committee of her peers.
Can the CIRS-BRAT framework also be used for drug delivery combination products?
Valid real-world evidence depends on being able to accurately identify exposures of interest in real-world data.